Opus Genetics CEO George Magrath, MD, discusses how the company introduced virtual reality-enabled assessments and relied on digital endpoints to better measure participants’ vision changes.
- Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It
- Accelerating Clinical Innovation With Open-Source Medical Platforms
- From Supercomputers To The Cloud: How Pharma's R&D Infrastructure Transformation Impacts Clinical Trials
- How To Identify Patient-Centric Risks In The TMF With AI And Automation
- How The TMF Demonstrates Patient Safety And Rights In DCTs
- Begin Your AI-Led Digital Clinical Transformation With A Phased Approach
- How AI Is Rewriting The Future Of TMF And Clinical Quality
- Penetration Testing In Healthcare: Common Vulnerabilities And Programs To Address Them
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
How eConsent Delivers Value For Sponsors
Delve into the data substantiating experiences with electronic informed consent to better understand their positive impact on the outcomes of clinical trials.
-
How Pfizer Used Wearable DHTs To Reveal Meaningful Treatment Effects In Cancer Cachexia
Wearable digital health technologies (DHTs) played a crucial role in assessing patient-centric outcomes during pfizer's study into the benefits of using ponsegromab for treating cancer cachexia.
-
How Can Electronic Data Capture Better Serve Decentralized Clinical Trials?
Newer, nimbler technology providers face a steep climb if they want to convince sponsors to sunset traditional EDC in favor of direct data capture only, or a unified decentralized trial platform that everything plugs into. Will EDC evolve to fix its existing problems, or will a different type of decentralized trial platform (or single platform model) replace pick-and-pull, add-and-subtract modules of clinical trial technology?
-
Achieving Self Sufficiency In Data Collection For Optinose
Uncover how this specialty pharmaceutical company was able to gain control over its EDC environment by adopting a solution their team could use in-house.
-
Broadening Eligibility Criteria Among Cancer Clinical Trials Patients
This study challenges the commonly applied exclusionary approach to clinical trials, particularly cancer trials, that underrepresent certain populations and limit the generalizability of research advancements.
-
The Transformative Role Of Digital Health Technologies
Digital health technologies are transforming clinical trials through decentralization, improved data, and patient-centric approaches, driving efficiency and accessibility.
-
Evaluating EDC Systems In A Modern DM Landscape
This guide provides five crucial recommendations to refine evaluation strategies and choose the right solution for today's complex clinical data environment, optimizing data collection practices.
-
Achieving Faster, Simpler Validation Through Crowdsource UAT
An approach most often seen in the larger tech space, crowdsource UAT can offer several potential advantages for the clinical trial industry and eTMF validation.
-
Why Oncology Drug Development Lags In Digital Biomarkers
Despite technological advances, oncology drug development research has lagged in adopting wearable digital biomarkers. Explore this space's unique challenges and the benefits of wearable technology.
-
Shaping The Future Of eCOA User Acceptance Testing
Proactive planning by sponsors and early User Acceptance Testing (UAT) involvement in the eCOA design process can substantially improve study quality, efficiency, and consistency.